Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response

Mario Frias; Antonio Rivero-Juarez; Ana Gordon; Angela Camacho; Sara Cantisan; Francisca Cuenca-Lopez; Julian Torre-Cisneros; Jose Peña; Antonio Rivero

doi:10.1371/journal.pone.0121019

Abstract

Objective

A prospective analysis of the distribution of NK subsets and natural cytotoxicity receptors (NKp30/NKp46) in HIV patients with long-term HAART use and sustained virological and immunological response.

Methods

The main inclusion criteria were: at least 3 years’ receipt of HAART; current CD4⁺ count ≥ 500 cells/mm³; undetectable viral load for at least 24 months; no hepatotropic virus co-infection. Percentages of CD56^dim, CD56^bright NK cells and CD56^neg CD16⁺ cells were obtained. Expression of the NCRs, NKp30 and NKp46 was analysed in CD56⁺ cells. Thirty-nine infected patients and sixteen healthy donors were included in the study.

Results

The percentages of total CD56⁺ and CD56^dim NK cells were significantly lower in HIV-infected patients than in healthy donors (70.4 vs. 50.3 and 80.9 vs. 66.1 respectively). The percentage of total CD56⁺ NK cells expressing NCR receptors was lower in HIV patients than in healthy donors (NKp30: 25.20 vs. 58.63; NKp46: 24.8 vs. 50.59). This was also observed for CD56^dim and CD56^bright NK cells. Length of time with undetectable HIV viral load was identified as an independent factor associated with higher expression of NKp30 and NKp46.

Conclusion

Despite the prolonged and effective use of HAART, HIV-infected patients do not fully reconstitute the distribution of NK cells. Length of time with an undetectable viral load was related to greater recovery of NKp30/NKp46 receptors.

Citation: Frias M, Rivero-Juarez A, Gordon A, Camacho A, Cantisan S, Cuenca-Lopez F, et al. (2015) Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response. PLoS ONE 10(3): e0121019. https://doi.org/10.1371/journal.pone.0121019

Academic Editor: Johan K. Sandberg, Karolinska Institutet, SWEDEN

Received: October 15, 2014; Accepted: February 9, 2015; Published: March 26, 2015

Copyright: © 2015 Frias et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: The study was funded by Fundación Progreso y Salud, Consejería de Salud de la Junta de Andalucía (grants for health research projects: refs. PI-0430/2012; PI-0247/2010; PI-0208/2008; PI-0124/2008; PI-0305/2009). AR has received a Research Extension Grant from the Consejería de Salud, Innovación y Ciencia de la Junta de Andalucía. ARJ is the recipient of a post-doctoral perfection grant, in the recently-qualified doctors category, from the Consejería de Igualdad, Salud y Políticas Sociales (RH-0024-2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Replication of the human immunodeficiency virus (HIV) triggers an abnormal pathological redistribution of the natural killer (NK) cells [1–2], which reduces the percentage of the cytolyticCD56^dim subpopulation and increases that of the dysfunctional CD56^negNK population [1, 3–7]. Furthermore, HIV replication leads to a reduced expression of the natural cytotoxicity receptors (NCR), NKp30, NKp44 and NKp46 [1, 8–9]. The reduction in the number of CD56⁺NK cells and down regulation of the activating receptors may limit the functionality of the innate immune response, so compromising the response to possible opportunistic infections or tumours [2,8].The suppression of HIV replication therefore could, in theory, imply a reversal of such abnormalities in the NK cells.

In the context of the suppression of viral load through highly active antiretroviral therapy (HAART), several authors have studied the influence of changes that may occur on NK cells, with discrepant results. On the one hand, the recovery of NK cell subsets and activating receptors to levels similar to those of healthy individuals has been reported when HIV patients have been on HAART for two years [9]. Other studies however have found incomplete NK subset recovery after initiating HAART when compared with T-cell recovery during the early months of therapy [10].

Given this controversy, further studies are needed to clarify what occurs in NK cells, which is an important arm of innate immune response in HIV infection. Furthermore, there are no studies of the frequency, phenotype and extent of recovery of NK cells in the context of prolonged and effective use of HAART.

Material and Methods

Study design

We designed a prospective study in order to analyse the distribution of NK cell subsets and NCRs in HIV patients with prolonged use of HAART and a sustained virological/immunological response.

Patients and variables collected

Chronic HIV-infected patients in follow-up in the Infectious Diseases Unit of the Hospital Universitario Reina Sofia (Cordoba, Spain) between December 2013 and April 2014were included. The main inclusion criteria were in receipt of HAART for at least 3 years; current CD4⁺count ≥ 500 cells/mm³,confirmed on two consecutive determinations; an undetectable viral load for at least 24 months, measured by PCR (CobasTaqMan, Roche Diagnostic Systems Inc., Pleasanton, CA, USA), with detection limit set at 20 IU/mL; and no hepatotropic virus co-infection. Data relating to age, sex, current CD4 count, nadir CD4 count, increased CD4, CD8, CD4/CD8 ratios, length of time with HAART and length of time with undetectable viral load were also collected. Healthy donors were included as controls and their data was collected and analyzed in parallel, under the same conditions and experiments as the HIV-infected patients.

NK subsets and NCR evaluation

Peripheral blood mononuclear cells (PBMCs) were isolated in 3 mL EDTA tubes by density gradient centrifugation (Ficoll-Hypaque). Isolated PBMCs were cryopreserved in liquid nitrogen, using a freezing medium composed of Fetal Bovine Serum (FBS) and 10% DMSO until analysis. NK cells and their subpopulations were defined on the basisoflive cells (Propidium Iodide) and the expression of CD3, CD16 and CD56 receptors in the peripheral blood lymphocyte region. Percentages of CD56^dim (CD3^neg, CD56^pos+, CD16^pos/neg), CD56^bright(CD3^neg, CD56^pos+++, CD16^pos/neg) and CD56^negCD16^pos(CD3^neg, CD56^neg, CD16^pos) cells were obtained. The CD56^pos-CD16^pos/neg cells were analysed for the expression of the natural cytotoxicity receptors, NKp30 and NKp46 (S1 Fig.).PBMCs were stained using anti-CD3-Vioblue (BW264/56), anti-CD16-APCVio770 (VEP13), anti-CD56-PEVio770 (AF12-7H3), anti-NKp30 (AF29-4d12), and anti-NKp46-APC (9E2). Propidiumiodide (PI) solution was used to assess cell viability. All antibodies and the PI were obtained from MiltenyiiBiotec (Germany). For acquisition, the MACSQuant (MiltenyiiBiotec, Germany) system was used. Data were analyzed using FlowJo Software (Tree Star, OR, USA).

Statistical analysis

Categorical variables were expressed as numbers of cases (percentages), and continuous variables as medians (interquartile range). Receptor expression and subpopulations were represented as percentages (median with IQR). Furthermore, normalized mean fluorescence intensity (NMFI) values were calculated for NKp30/46 receptors. Continuous variables were analysed using the Mann Whitney U-test; categorical variables were analysed by applying Fisher’s exact test. The Spearman correlation test was used for bivariate analysis. Five linear regression models were performed to identify independent predictors of the frequencies of NK cell subsets (total CD56⁺, CD56^dim, CD56^bright NK cells) and natural cytotoxicity receptor expression (NKp30 and NKp46). The coefficients (b) of the models were shown as adjusted coefficients. The analysis was performed using the SPSS statistical software package, version 18.0 (IBM Corporation, Somers, New York, USA).

Among HIV-infected patients, the relationship between percentages of NK cells (subsets, NKp30⁺ and NKp46⁺ cells) was studied, as well as various clinical variables, such as AIDS/non-AIDS-defining conditions, nadir CD4⁺ count, current CD4⁺ count, increase in CD4⁺, age, and length of time with undetectable HIV viral load. For each variable, the patients were sorted into two groups with respect to the median of the variable.

Ethical statement

The study was designed and performed according to the Helsinki Declaration and was approved by the ethics committee of the Reina Sofía University Hospital, Cordoba, Spain. All of the patients provided written informed consent before participating in the study and gave permission for biological samples to be stored and processed.

Results

Study population

Thirty-nine infected patients and sixteen healthy donors were included in the study. The median age of patients was 43 years (IQR, 35–51 years), and 31 (79.5%) were men. Twelve (30.7%) patients had AIDS-defining conditions in the past. 38 (97.4%) had risky sexual practices and 1 of them had had parenteral drugs in the past. The nadir CD4⁺ count (median) was 258 cells/mL (IQR, 100–342 cells/mL). CurrentCD4⁺ and CD8⁺ counts were 652 cells/mL (IQR, 594–880cells/mL) and 741 cells/mL (IQR, 586–1034 cells/mL), respectively. Length of time on HAART was 93 months (IQR, 53–139 months), and length of time with undetectable HIV viral load was 85 months (IQR, 47–128 months). The median age of healthy donors was 36.50 years (IQR, 29.75–47.25 years), and 10 (62.5%) were men.

NK cell distribution and NCR expression in HIV-infected patients as compared with healthy donors

Total CD56⁺ NK cell counts (percentage among CD3^neg cells) were lower in HIV-infected patients than in healthy donors (50.3 [37.6–65.2] vs. 70.4 [48.3–81.1]; p<0.001). CD56^dim percentages were significantly lower in HIV-infected patients than in healthy donors (66.1 [52.9–75.8] vs. 80.9 [75.6–82.9]; p<0.001) and the percentage of CD56^negCD16⁺cells was higher in HIV-infected patients than in the control group (28.9 [18.5–36.9] vs. 13.7 [10.7–16.7]; p<0.001). No differences in percentages of CD56^bright NK cells were found between the HIV-infected group and healthy donors (5.88 [3.5–8] vs. 5.18 [4.5–7.2]; p = 0.902). The percentage of CD56⁺ NK cells expressing NKp30 and NKp46 receptors was lower in HIV patients than in healthy donors (Fig. 1). Furthermore, when the normalized mean fluorescence intensity values of the two groups were compared, HIV patients had a lower density of NKp30/NKp46 than healthy donors. (Fig. 1). The same phenomenon was also found for CD56^dim andCD56^brightcells. (Fig. 1).

Download:

Fig 1. Flow cytometric analysis of NKp30 and NKp46 natural cytotoxicity receptors.

The figure shows the percentage of cells expressing NKp30 and NKp46 and normalized mean fluorescence intensity values for total CD56+ NK cells and CD56^dimand CD56^bright subsets. The values are expressed as medians with interquartile range. The analysis compared HIV-infected patients and healthy donors.

https://doi.org/10.1371/journal.pone.0121019.g001

Factors associated with higher NCR expression in HIV-infected patients

There was no correlation between the percentage of NCR expression and nadir CD4⁺count, current CD4⁺ count, increased CD4⁺, AIDS/non-AIDS defining conditions or age. However, a higher and statistically significant percentage of NK cells expressing NKp30 and NKp46 (Table 1) was found in patients who had achieved more than 85 months of undetectable viral load. There was also no correlation between these variables and frequencies of NK cell subsets (S1 Table).

Download:

Table 1. Percentages of NKp30+ and NKp46+ cells among HIV-patients according to various clinical variables.

https://doi.org/10.1371/journal.pone.0121019.t001

There was a positive correlation between the percentage of NK cells expressing NKp30 (Spearman rho, r = 0.47 p = 0.002) and NKp46 receptors (Spearman rho, r = 0.45 p = 0.004) and length of time with undetectable viral load (Fig. 2). Furthermore, a multivariate linear regression model identified length of time with an undetectable viral load as the only independent factor for NKp30 and NKp46 expression (Table 2).

Download:

Fig 2. Graph for bivariate analysis between time with undetectable viral load and frequency of NKp30/NKp46+ cells.

The percentage of NK cells expressing NKp30 (Spearman rho, r = 0.47 p = 0.002) and NKp46 receptors (Spearman rho, r = 0.45 p = 0.004) correlate positively with length of time with undetectable viral load.

https://doi.org/10.1371/journal.pone.0121019.g002

Download:

Table 2. Multivariate linear regression model for percentage of NKp30+ and NKp46+ cells.

https://doi.org/10.1371/journal.pone.0121019.t002

Discussion

Our results suggest that, in spite of the prolonged use of HAART, a long period with an undetectable viral load and a remarkable increase in CD4⁺ count, HIV-infected patients were unable to completely restore the innate immunity mediated by NK cells, and showed a decreased proportion of CD56⁺ cells, particularly the cytolytic CD56^dim subpopulation, and low expression of NCRs.

In addition, we also found an increase in the percentage of CD56^neg-CD16⁺ cells in HIV-infected patients, although, in our study, we cannot consider them to be specific NK cells. Indeed, there remain many unanswered questions about the phenotype, function, and biology of CD3^negCD56^negCD16⁺ cells and the lack of NK cell lineage-specific markers makes it difficult to study this NK cell subset.

In this respect, there are studies that have described this subset as cells with impaired or altered cytolytic function [11]. However, recent studies have shown, based on the expression of CD7, that CD56^neg-CD16⁺ cells in HIV infection are a mixed population of myeloid and NK cells, where CD7⁺CD56^negCD16⁺ are mature NK cells without a significantly altered phenotype [12,13]. Further analysis is required to understand what happens to these cells in the context of HIV infection.

In other studies that studied the recovery of NK cells in the context of HIV, Michaëlsson et al. [14] analyzed the reconstitution of NK cells in patients with and without treatment. Although the follow-up was only one year, they did not find clear differences in the frequencies of NK subsets and percentages of NKp30/46⁺ cells between those patients who had been treated and those who had not.

Chemini et al.[10] analyzed NK cell compartments in relation to CD4 recovery in 21 HIV-infected subjects who were followed to <50 copies/ml after starting antiretroviral therapy (ART) and were observed for 52 weeks of sustained suppression. Although the CD4 count increased in all subjects in response to ART, the restoration of total NK cells was incomplete even after 52 weeks of this therapy. In our study, 20 patients received HAART for over 93 months and HIV RNA suppression was maintained for over 85 months, with a median CD4⁺recovery of 458 cells/mL; nonetheless the distribution of NK cell populations was not restored. These results suggest that the recovery of innate immunity after very prolonged viral suppression (over 7 years) is still incomplete and does not reach healthy levels. Innate immunity is known to play a fundamental role in the early defence against pathogens and to exert regulatory control on adaptive responses downstream. The incomplete recovery of innate immunity may lead to patients remaining susceptible to tumours and various viral infections [15–16].

In our study, the only factor associated with any degree of reconstitution of the NK cells was length of time with an undetectable HIV-1 RNA. We observed a positive correlation between the percentage of NK cells expressing NKp30 and NKp46 receptors and length of time with an undetectable HIV-1 viral load. Indeed, patients with more than 85 months showed higher percentages of NKp30- and NKp46-positive cells than those with less than 85 months. In this regard, a greater number of cells positive for these receptors may imply a better response and NK cell activity [1,17]. This finding suggests that a more prolonged and effective antiretroviral therapy may lead to restoration of innate immunity in the long-term, although the difference between the percentage of NCR⁺ cells in groups of patients with more than 85 months of viral suppression and healthy donors remains unbalanced.

In this work, CD4⁺countand CD4⁺ increase from basal were not related to the extent of NK cell reconstitution, which suggests that simply determiningtheCD4⁺ cell count alone in quantitative terms in order to assess the immune status of HIV-infected patients provides only limited information. Thus, Bisio et al. [18] observed that HIV-infected patients with low CD4⁺ cell counts and AIDS-defining opportunistic infections had a differential expression of NK cell activating receptors when compared with HIV-infected patients with similar nadir CD4+ cell counts but who had never had an AIDS-defining condition.

The present study has several limitations. Firstly, the low number of patients included may not have enough statistical power to detect differences between HIV groups of patients on the basis of various clinical variables, such as AIDS/non-AIDS status. Secondly, other potentially related variables, such as length of time with active HIV infection, were not collected. Lastly, functional assays were not performed.

In conclusion, despite the prolonged and effective use of HAART, HIV-infected patients do not reconstitute the pathological NK cell distribution associated with HIV infection. In our study, length of time with undetectable viral load was associated with the greater recovery of NKp30/NKp46 receptors of natural killer cells. Studies evaluating the impact of prolonged HAART on NK cell restitution are needed.

Supporting Information

S1 Fig. Flow cytometric gating strategy for analysis of NK cell subsets and NCR expression.

(A) PBL gating was performed on the basis of FSC and SSC parameters. CD56⁺ cells and CD56^dim, CD56^bright and CD56^neg CD16⁺ subpopulations were defined according to their expression of CD3, CD16 and CD56 in the PBL region and propidium iodide (PI) was used to assess cell viability. Unstained samples were used as negative controls for all receptors. (B) Dot-plots represents expression of NKp30 and NKp46 in CD56⁺ cells.

https://doi.org/10.1371/journal.pone.0121019.s001

(PPT)

S1 Table. Percentages of NK subsets among HIV-infected patients, according to various clinical variables.

Percentages of NK subpopulations are presented as median and interquartile range (Q1-Q3). The percentage of “Total CD56⁺” was calculated with respect to CD3^neg cells. The p values were obtained by the Mann–Whitney U test. Legend: ^a undetectable viral load.

https://doi.org/10.1371/journal.pone.0121019.s002

(DOC)

Author Contributions

Conceived and designed the experiments: MF ARJ AR. Performed the experiments: MF ARJ AG. Analyzed the data: MF ARJ AG AC AR. Contributed reagents/materials/analysis tools: SC FCL JTC. Wrote the paper: MF ARJ AR. Critical review of the manuscript: ARJ AG AC SC FCL JTC JP AR.

References

1. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol, 2005. 5(11): p. 835–43. pmid:16239902
2. De Maria A, Moretta L. NK cell function in HIV-1 infection. Curr HIV Res, 2008. 6(5): p. 433–40. pmid:18855653
3. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood, 2005. 106(10): p. 3366–9. pmid:16002429
4. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes.J Leukoc Biol, 2010. 88(6): p. 1119–30. pmid:20651298
5. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A, 2005. 102(8): p. 2886–91. pmid:15699323
6. Scott-Algara D, Paul P. NK cells and HIV infection: lessons from other viruses. Curr Mol Med, 2002. 2(8): p. 757–68. pmid:12462395
7. Hu PF, Hultin LE, Hultin P, Hausner MA, Hirji K, Jewett A, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol, 1995. 10(3): p. 331–40. pmid:7552495
8. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44).Eur J Immunol, 2003. 33(9): p. 2410–8. pmid:12938217
9. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A, 2003. 100(25): p. 15011–6. pmid:14645713
10. Chehimi J, Azzoni L, Farabaugh M, Creer SA, Tomescu C, Hancock A, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol, 2007. 179(4): p. 2642–50. pmid:17675528
11. Björkström NK, Ljunggren HG, Sandberg JK. CD56-negative NK cells: origin,function, and role in chronic viral disease. Trends Immunol, 2010. 31(11): p. 401–6. pmid:20829113
12. Milush JM, Long BR, Snyder-Cappione JE, Cappione AJ, York VA, Ndhlovu LC, et al. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood, 2009. 114(23): p. 4823–31. pmid:19805616
13. Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, Hecht FM, et al. CD56negCD16+ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology, 2013. 10:158 pmid:24351015
14. Michaëlsson J, Long BR, Loo CP, Lanier LL, Spotts G, Hecht FM, et al. Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis. 2008, 197(1): p. 117–25 pmid:18171294
15. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol, 2013. 31: p. 163–94. pmid:23298212
16. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol, 2002. 3(1): p. 6–8. pmid:11753399
17. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et al. Human natural killer cell receptors and co-receptors. Immunol Rev, 2001. 181: p. 203–14. pmid:11513142
18. Bisio F, Bozzano F, Marras F, Di Biagio A, Moretta L, De Maria A. Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. Immunol Lett, 2013. 152(1): p. 16–24. pmid:23538009

[ref1] 1. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol, 2005. 5(11): p. 835–43. pmid:16239902
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. De Maria A, Moretta L. NK cell function in HIV-1 infection. Curr HIV Res, 2008. 6(5): p. 433–40. pmid:18855653
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood, 2005. 106(10): p. 3366–9. pmid:16002429
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes.J Leukoc Biol, 2010. 88(6): p. 1119–30. pmid:20651298
View Article
PubMed/NCBI
Google Scholar

[14] View Article

[15] PubMed/NCBI

[16] Google Scholar

[ref5] 5. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A, 2005. 102(8): p. 2886–91. pmid:15699323
View Article
PubMed/NCBI
Google Scholar

[18] View Article

[19] PubMed/NCBI

[20] Google Scholar

[ref6] 6. Scott-Algara D, Paul P. NK cells and HIV infection: lessons from other viruses. Curr Mol Med, 2002. 2(8): p. 757–68. pmid:12462395
View Article
PubMed/NCBI
Google Scholar

[22] View Article

[23] PubMed/NCBI

[24] Google Scholar

[ref7] 7. Hu PF, Hultin LE, Hultin P, Hausner MA, Hirji K, Jewett A, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol, 1995. 10(3): p. 331–40. pmid:7552495
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref8] 8. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44).Eur J Immunol, 2003. 33(9): p. 2410–8. pmid:12938217
View Article
PubMed/NCBI
Google Scholar

[30] View Article

[31] PubMed/NCBI

[32] Google Scholar

[ref9] 9. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A, 2003. 100(25): p. 15011–6. pmid:14645713
View Article
PubMed/NCBI
Google Scholar

[34] View Article

[35] PubMed/NCBI

[36] Google Scholar

[ref10] 10. Chehimi J, Azzoni L, Farabaugh M, Creer SA, Tomescu C, Hancock A, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol, 2007. 179(4): p. 2642–50. pmid:17675528
View Article
PubMed/NCBI
Google Scholar

[38] View Article

[39] PubMed/NCBI

[40] Google Scholar

[ref11] 11. Björkström NK, Ljunggren HG, Sandberg JK. CD56-negative NK cells: origin,function, and role in chronic viral disease. Trends Immunol, 2010. 31(11): p. 401–6. pmid:20829113
View Article
PubMed/NCBI
Google Scholar

[42] View Article

[43] PubMed/NCBI

[44] Google Scholar

[ref12] 12. Milush JM, Long BR, Snyder-Cappione JE, Cappione AJ, York VA, Ndhlovu LC, et al. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood, 2009. 114(23): p. 4823–31. pmid:19805616
View Article
PubMed/NCBI
Google Scholar

[46] View Article

[47] PubMed/NCBI

[48] Google Scholar

[ref13] 13. Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, Hecht FM, et al. CD56negCD16+ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology, 2013. 10:158 pmid:24351015
View Article
PubMed/NCBI
Google Scholar

[50] View Article

[51] PubMed/NCBI

[52] Google Scholar

[ref14] 14. Michaëlsson J, Long BR, Loo CP, Lanier LL, Spotts G, Hecht FM, et al. Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis. 2008, 197(1): p. 117–25 pmid:18171294
View Article
PubMed/NCBI
Google Scholar

[54] View Article

[55] PubMed/NCBI

[56] Google Scholar

[ref15] 15. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol, 2013. 31: p. 163–94. pmid:23298212
View Article
PubMed/NCBI
Google Scholar

[58] View Article

[59] PubMed/NCBI

[60] Google Scholar

[ref16] 16. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol, 2002. 3(1): p. 6–8. pmid:11753399
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref17] 17. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et al. Human natural killer cell receptors and co-receptors. Immunol Rev, 2001. 181: p. 203–14. pmid:11513142
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref18] 18. Bisio F, Bozzano F, Marras F, Di Biagio A, Moretta L, De Maria A. Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. Immunol Lett, 2013. 152(1): p. 16–24. pmid:23538009
View Article
PubMed/NCBI
Google Scholar

[70] View Article

[71] PubMed/NCBI

[72] Google Scholar

Figures

Abstract

Objective

Methods

Results

Conclusion

Introduction

Material and Methods

Study design

Patients and variables collected

NK subsets and NCR evaluation

Statistical analysis

Ethical statement

Results

Study population

NK cell distribution and NCR expression in HIV-infected patients as compared with healthy donors

Factors associated with higher NCR expression in HIV-infected patients

Discussion

Supporting Information

S1 Fig. Flow cytometric gating strategy for analysis of NK cell subsets and NCR expression.

S1 Table. Percentages of NK subsets among HIV-infected patients, according to various clinical variables.

Author Contributions

References